JP2009513712A5 - - Google Patents

Download PDF

Info

Publication number
JP2009513712A5
JP2009513712A5 JP2008538984A JP2008538984A JP2009513712A5 JP 2009513712 A5 JP2009513712 A5 JP 2009513712A5 JP 2008538984 A JP2008538984 A JP 2008538984A JP 2008538984 A JP2008538984 A JP 2008538984A JP 2009513712 A5 JP2009513712 A5 JP 2009513712A5
Authority
JP
Japan
Prior art keywords
antibody
disease
composition
human
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008538984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/042601 external-priority patent/WO2007053661A2/en
Publication of JP2009513712A publication Critical patent/JP2009513712A/ja
Publication of JP2009513712A5 publication Critical patent/JP2009513712A5/ja
Pending legal-status Critical Current

Links

JP2008538984A 2005-11-01 2006-11-01 抗ｃｄ４０抗体の使用 Pending JP2009513712A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73258005P 2005-11-01 2005-11-01
PCT/US2006/042601 WO2007053661A2 (en) 2005-11-01 2006-11-01 Uses of anti-cd40 antibodies

Publications (2)

Publication Number Publication Date
JP2009513712A JP2009513712A (ja) 2009-04-02
JP2009513712A5 true JP2009513712A5 (https=) 2010-12-09

Family

ID=38006484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008538984A Pending JP2009513712A (ja) 2005-11-01 2006-11-01 抗ｃｄ４０抗体の使用

Country Status (12)

Country Link
US (1) US20090202531A1 (https=)
EP (1) EP1957538B1 (https=)
JP (1) JP2009513712A (https=)
KR (1) KR101395005B1 (https=)
CN (1) CN101351478A (https=)
AU (1) AU2006308860B2 (https=)
BR (1) BRPI0618217A2 (https=)
CA (1) CA2627891A1 (https=)
ES (1) ES2428089T3 (https=)
IL (1) IL191117A (https=)
RU (1) RU2442606C2 (https=)
WO (1) WO2007053661A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2400660T3 (es) 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
BRPI1007222A2 (pt) 2009-01-06 2016-02-23 Inserm Inst Nat De La Santé Et De La Rech Médicale agente de depleção de células b para tratamento de aterosclerose
WO2011006119A2 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
RU2509573C2 (ru) * 2010-07-27 2014-03-20 Олег Ильич Эпштейн Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2441023C1 (ru) * 2010-07-15 2012-01-27 Олег Ильич Эпштейн Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
EP4086605B1 (en) * 2011-06-17 2025-06-11 Roche Diagnostics Hematology, Inc. Solution and method for histoprocessing of biological samples
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN108025068A (zh) * 2014-03-12 2018-05-11 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns的疾病和损伤
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
BR112018006251A2 (pt) * 2015-09-30 2018-10-16 Janssen Biotech Inc anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CN111344304B (zh) * 2017-06-01 2023-09-01 Pb免疫治疗公司 新型抗cd40抗体及其用途
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022120038A1 (en) * 2020-12-02 2022-06-09 Albert Einstein College Of Medicine Method for predicting patient response to cd40-targeted therapies
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240343817A1 (en) * 2021-07-14 2024-10-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibody that specifically recognizes cd40 and application thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023198194A1 (en) * 2022-04-15 2023-10-19 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-cd40 antibodies and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
NZ273504A (en) * 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2003035904A2 (en) * 2001-10-19 2003-05-01 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
SI1682177T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
ATE447412T1 (de) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
KR101128777B1 (ko) * 2003-11-04 2012-04-13 조마 테크놀로지 리미티드 다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
PL1680141T3 (pl) * 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
WO2005044307A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use

Similar Documents

Publication Publication Date Title
JP2009513712A5 (https=)
TWI508742B (zh) 治療性抗體之組合物及使用方法
TWI740384B (zh) 抗cd40抗體及其用途
JP5751631B2 (ja) Ｔｏｌｌ様受容体３アンタゴニスト
AU2013206788B2 (en) Method of providing monoclonal auto-antibodies with desired specificity
US20240122985A1 (en) Antibodies, combinations comprising antibodies, biomarkers, uses & methods
RU2008121899A (ru) Применение анти-cd40-антител
JP2018197250A (ja) コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合する抗体によって状態を治療する方法
US20080227704A1 (en) CXCL13 binding proteins
HUE035240T2 (hu) Készítmények és eljárások az izomerõ növelésére
KR20080068004A (ko) 뉴 월드 영장류 구조형성영역을 가진 조작 항체
TW201125876A (en) Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
CN109983032B (zh) Tim-3抗体、其抗原结合片段及医药用途
JP2011506406A (ja) ヒトｎｋｇ２ｄに対する抗体とその使用
JP2007510666A5 (https=)
AU2016200359A1 (en) Neutralizing Anti-CCL20 Antibodies
CN102782148A (zh) 与多种cc趋化因子结合的抗因子抗体
CN107266571A (zh) 抗‑mcam抗体及相关使用方法
KR20140003467A (ko) 항il-18 항체 및 그의 용도
BRPI0707425A2 (pt) construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio
US20170051053A1 (en) Method of providing monoclonal auto-antibodies with desired specificity
JP2012524524A (ja) ＩＬ−１２レセプターβ１サブユニットに特異的な治療用抗体の組成物および使用方法
JP2020169179A (ja) コロニー刺激因子１受容体（ｃｓｆ１ｒ）に結合する抗体で疾患を治療する方法
CN101287762A (zh) 具有新世界灵长类构架区的经改造的抗体
CN104829716A (zh) 用于治疗疾病的抗人sema4A抗体